CompanyGraph
Chengdu Easton Bio Pharmaceuticals Co., Ltd.
688513 · SSE · China
eastonpharma.cnFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.35B, above the global median of $1.18B
- FinancialsAltman Z-Score 8.73: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.96%Below 5Y avg (1.14%)
Annual Rate
CNY 0.49Paid annual
Payout Ratio
30.6%Sustainable
Last Ex-Dividend
Jun 2, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
9.05BCNY1.35B · vs all stocks (USD)
Trailing P/E
32.03xvs Biotechnology peers
Revenue (TTM)
1.34BCNY199.40M · vs all stocks (USD)
Profit Margin
20.75%vs Biotechnology peers
Beta
0.0390xvs all stocks
52-Week Change
-15.78%vs all stocks
Market Capitalization
9.05BCNY1.35B · vs all stocks (USD)
Enterprise Value
7.46BCNY1.11B · vs all stocks (USD)
Trailing P/E
32.03xvs Biotechnology peers
Forward P/E
24.52xvs Biotechnology peers
Price to Sales (TTM)
6.77xvs Biotechnology peers
Price to Book (MRQ)
3.03xvs Biotechnology peers
Enterprise to Revenue
5.58xvs Biotechnology peers
Enterprise to EBITDA
28.37xvs Biotechnology peers
Gross Margin
75.31%vs Biotechnology peers
Profit Margin
20.75%vs Biotechnology peers
Operating Margin
16.15%vs Biotechnology peers
Return on Assets (TTM)
2.71%vs Biotechnology peers
Return on Equity (TTM)
8.59%vs Biotechnology peers
Revenue (TTM)
1.34BCNY199.40M · vs all stocks (USD)
Revenue per Share (TTM)
7.71CNYUpdated Sep 22, 2026Quarterly Revenue Growth
-4.60%vs Biotechnology peers
Gross Profit (TTM)
1.00BCNY149.81M · vs all stocks (USD)
EBITDA (TTM)
262.66MCNY39.21M · vs all stocks (USD)
Net Income (TTM)
277.24MCNY41.38M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.90%vs Biotechnology peers
Operating Cash Flow (TTM)
274.86MCNY41.03M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
156.39MCNY23.34M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.4900CNYUpdated Sep 22, 2026Trailing Annual Dividend Yield
0.96%vs all stocks
5-Year Average Dividend Yield
1.14%vs all stocks
Payout Ratio
30.63%vs Biotechnology peers
Minority Interest (Equity)
106.14MCNYFY2025 · Dec 31, 2025Revenue
1.33BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
329.52MCNYFY2025 · Dec 31, 2025Gross Profit
1.00BCNYFY2025 · Dec 31, 2025Operating Income
252.56MCNY37.70M · vs all stocks (USD)
Pre-tax Income
299.65MCNYFY2025 · Dec 31, 2025Income Tax Expense
26.08MCNYFY2025 · Dec 31, 2025Net Income
273.57MCNYFY2025 · Dec 31, 2025EBIT
302.16MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
381.77MCNYFY2025 · Dec 31, 2025Research & Development
265.06MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
376.46MCNYFY2025 · Dec 31, 2025Other Operating Expenses
19.78MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
13.10MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.51MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.63CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.63CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
174.27MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
174.27MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
273.57MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
10.49MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
205.58MCNYFY2025 · Dec 31, 2025Free Cash Flow
119.70MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
836.88MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
273.57MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.03MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-23.86MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-48.17MCNYFY2025 · Dec 31, 2025Capital Expenditures
-85.87MCNYFY2025 · Dec 31, 2025Purchase of Investments
-19.68MCNYFY2025 · Dec 31, 2025Other Investing Activity
-260.90MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-366.45MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
55.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-73.67MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-76.79MCNYFY2025 · Dec 31, 2025Other Financing Charges
69.14MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-26.32MCNYFY2025 · Dec 31, 2025Shares Outstanding
176.53MSharesUpdated Sep 22, 2026Float Shares
79.68MSharesUpdated Sep 22, 2026% Held by Insiders
50.29%vs all stocks
% Held by Institutions
12.56%vs all stocks
Total Cash (MRQ)
1.67BCNY249.66M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.64CNYUpdated Sep 22, 2026Total Debt (MRQ)
148.75MCNY22.20M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0492xvs Biotechnology peers
Current Ratio (MRQ)
3.25xvs Biotechnology peers
Book Value per Share (MRQ)
16.90CNYUpdated Sep 22, 2026Total Assets
3.80BCNY566.91M · vs all stocks (USD)
Total Current Assets
2.13BCNYFY2025 · Dec 31, 2025Total Liabilities
758.90MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.67BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
140.21MCNYFY2025 · Dec 31, 2025Total Current Liabilities
618.70MCNYFY2025 · Dec 31, 2025Cash
836.09MCNYFY2025 · Dec 31, 2025Cash Equivalents
19.34MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
855.43MCNYFY2025 · Dec 31, 2025Other Short-term Investments
758.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
181.29MCNYFY2025 · Dec 31, 2025Inventory
228.71MCNYFY2025 · Dec 31, 2025Accounts Payable
124.98MCNYFY2025 · Dec 31, 2025Short-term Debt
115.11MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.04MCNYFY2025 · Dec 31, 2025Long-term Debt
31.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
176.53MCNYFY2025 · Dec 31, 2025Retained Earnings
1.33BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.04BCNY453.63M · vs all stocks (USD)
Treasury Stock
67.67MCNYFY2025 · Dec 31, 202552-Week Low
40.25CNYUpdated Sep 22, 202652-Week High
80.48CNYUpdated Sep 22, 202652-Week Change
-15.78%vs all stocks
Beta
0.0390xvs all stocks
50-Day MA
48.03CNYUpdated Sep 22, 2026200-Day MA
56.30CNYUpdated Sep 22, 2026Avg 10-Day Volume
2.22MSharesUpdated Sep 22, 2026Avg 30-Day Volume
2.34MSharesUpdated Sep 22, 2026Diluted EPS (TTM)
1.60CNYUpdated Sep 22, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 8.73: safe zoneNotable
Altman Z-Score: 8.73
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.35B, above the global median of $1.18BNotable
Market cap (USD): 1,350,487,204.972Global Median: 1,180,223,658.953
Levered free cash flow is $23.34M, above the global median of $18.73MNotable
Levered free cash flow (USD): 23,344,848.789Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
EL.En. S.p.A.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GenFleet Therapeutics (Shanghai) Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sinonep-Allsino Bio Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Alpha Tau Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Conmed Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Beijing Hotgen Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zhejiang Garden Bio-chemical High-tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Oric Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vcanbio Cell & Gene Engineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chongqing Genrix Biopharma Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Yamaichi Electronics Co., Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedHigh Retained Earnings With Profitability And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Simpson Manufacturing Co., Inc.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedHigh Retained Earnings With Profitability And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Pilot Corp.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedHigh Retained Earnings With Profitability And EquityMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities